proficient mismatch repair (pMMR) proteins
pMMR status indicates intact mismatch repair function. This classification informs immunotherapy eligibility decisions.
Where this biomarker is used
Each approval combines this biomarker with a specific indication and therapy. Select a therapy in the tables below to open its FDA-defined testing pathway.
Approvals where proficient mismatch repair (pMMR) proteins is defined directly in the indication labeling.
| Indication | Biomarker criteria | Therapies |
|---|---|---|
Endometrial Carcinoma (EC) Solid Tumor · Endometrium |
|
Approvals defined at the solid tumor level where proficient mismatch repair (pMMR) proteins is part of the eligibility criteria.
No tumor-agnostic approvals are currently mapped for this biomarker.
Tests that measure this biomarker
These assays report proficient mismatch repair (pMMR) proteins as part of their validated menu. In many cases they are identified in FDA labeling as acceptable companion diagnostics for specific approvals.
Reports proficient mismatch repair (pMMR) proteins as part of its biomarker panel.